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IntroductIon
Maternal obesity may be associated with metabolic factors 
that affect the intrauterine environment, fetal growth, and the 
offspring’s long-term risk for chronic disease (1,2). However, 
the physiologic pathways mediating the effects of maternal 
obesity are not well characterized. Changes in maternal lipid 
metabolism are a normal physiologic response to pregnancy. 
Progressive increases of circulating lipids, which optimize the 
availability of substrates necessary for fetal growth and devel-
opment (3–6), have been consistently demonstrated to influ-
ence the intrauterine environment and fetal outcomes. There 
is growing evidence that obese individuals may exhibit dis-
tinct metabolic patterns that may influence lipid homeostasis 
and the development of many of the pathological conditions 
associated with obesity (7–9). We have recently shown that 
such metabolic differences may be associated with differences 
in maternal lipid profiles during pregnancy (10). However, 
few studies have documented how differences in the meta-
bolic response of obese mothers may affect the relationship 
between maternal lipids and fetal growth and development.
In cross-sectional studies, maternal serum triglyceride (TG) 
levels in mid to late second trimester are positively associ-
ated with birth weight (BW) after adjusting for maternal BMI 
(11–13); likewise, decreased levels of maternal total choles-
terol (TC), and low-density lipoprotein cholesterol (LDL-C) 
have been associated with intrauterine growth restriction (5). 
Case–control studies have also reported inverse associations 
between maternal high-density lipoprotein cholesterol (HDL-
C) levels and risk of macrosomia (5,12,14,15). In addition to 
influencing fetal growth, such metabolic factors may also result 
in fetal responses that have long-term health consequences; 
for example, maternal hypercholesterolemia has been linked 
to increased cholesterol deposition in the fetal aorta that may 
influence risk of long-term morbidity (16). However, these 
studies do not directly address the possibility that the distinct 
metabolic patterns found in obese and nonobese women may 
result in qualitatively different effects on the growing fetus.
The goal of this study was to estimate the influence of vari-
ation in maternal lipid levels during pregnancy on variation 
in infant BW in women with overweight/obese prepregnancy 
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BMI (>25.0) and normal prepregnancy BMI (≤25.0). We spe-
cifically monitored these women at multiple time points across 
gestation in order to gain insight into the influence of longitu-
dinal variation in lipid levels on infant BW.
Methods and Procedures
study sample
We recruited 152 participants as part of an ongoing prospective cohort 
study of pregnant women at the University of Michigan Health System 
(Ann Arbor, MI). The institutional review board of the University of 
Michigan Medical School (Ann Arbor, MI) approved the study pro-
tocols. Eligible participants were 18–45 years of age, between 6 and 10 
weeks gestation with a singleton pregnancy, and intended to deliver at 
the study hospital. Informed consent was obtained at the initial visit. 
Data and laboratory samples were collected at five time points during 
pregnancy: 6–10, 10–14, 16–20, 22–26, and 32–36 weeks gestation. 
At each time point, we obtained data from a brief interview, maternal 
anthropometric measurements, fetal ultrasound measurements, and 
maternal blood draw. Data analyses were carried out on the cohort of 
143 participants who completed the study and delivered a live infant. 
Fewer than 1% of women were excluded from any particular analysis 
because of missing data.
data collection and variables
Baseline maternal demographic and health characteristics were col-
lected by questionnaire upon entry into the study as well as subsequent 
review of medical records. Changes in maternal health characteristics 
were assessed at each subsequent time point. Standing height was meas-
ured at the baseline visit using a wall-mounted stadiometer. Weight was 
measured at each time point in light street clothes, without shoes, on a 
calibrated electronic scale (Scale-tronix, White Plains, NY). Maternal 
prepregnancy weight was collected by self-report at the initial visit. 
Prepregnancy BMI was calculated using height and prepregnancy 
weight (BMI = weight/height (2)), and categorized into two levels using 
World Health Organization cutoff points as normal weight (≤25.0 kg/
m2) and overweight/obese (>25.0 kg/m2) based on the most recent 
 recommendations of the Institute of Medicine (17).
At each time point, maternal venous blood from nonfasting partici-
pants was collected in a standard serum separator tube and allowed to 
clot for 30 min before centrifugation for 15 min at 1,000g. While the use of 
nonfasting blood samples may lead to greater variation in lipid levels, par-
ticularly TG, previous research has shown that it is unlikely to introduce 
systematic bias, either across time or between BMI categories that would 
alter the associations reported here. Prior studies of nonpregnant adults 
have shown that lipid profiles change only minimally in response to food 
intake (18), show high correlations between fasting and postprandial 
levels (19) and are similarly associated with disease risk in both the fasting 
and nonfasting state (18,20,21). Accordingly, in pregnant women, at least 
one prior study has shown that plasma lipids do not appreciably change 
with time after a meal (22). In addition, nonfasting samples are signifi-
cantly associated with pregnancy outcomes consistent with studies using 
fasting blood samples to determine lipid concentrations (15,22,23).
Serum was immediately aliquotted and stored at −20 °C. Quantitative 
lipid assays were performed in the Chemistry Laboratory of the Michigan 
Diabetes Research and Training Center using standard methods. Serum 
TC was enzymatically determined using reagent for cholesterol (no. 
3313018; Roche Diagnostics, Indianapolis, IN). Serum TG was measured 
using a colorimetric enzymatic assay (no. 3034658; Roche Diagnostics). 
Serum LDL-C was measured using the LDL Direct Liquid Select system 
(no. 7120; Equal Diagnostics, Exton, PA). HDL-C was measured directly 
using the HDL Direct reagent (no. 3034569; Roche Diagnostics).
Infant variables, including date of delivery, BW, and gender, were 
collected at delivery. An ultrasound estimate of gestational age was 
determined by early first trimester ultrasound. Since BW varies signifi-
cantly with gestational age, the BW was regressed onto gestational age. 
The residual values from each fit were used to represent the gestational 
age–adjusted BW (aBW). These residuals were then used as the depend-
ent variable for the modeling of the relationship of aBW to maternal 
serum lipids as described below.
statistical analysis
All statistical analyses were performed using SAS version 9.1 (SAS 
Institute, Cary, NC). Univariate regression models were used to describe 
the demographic characteristics of the study sample and tested the 
hypothesis of homogeneity of the means between BMI  categories. The 
Fisher exact test was used to assess statistical significance of categorical 
variables; the t-test was used for continuous variables. We then tested the 
hypothesis that variation in aBW is not influenced by variation in lipid 
levels measured at each time point for each BMI category. Univariate and 
multivariable regression analyses were used to model the cross-sectional 
relationship between aBW and maternal lipid levels at each time point. 
Analyses were stratified on maternal prepregnancy BMI as noted above. 
A P value of <0.05 was considered significant. We used a standard longi-
tudinal analytic approach to estimate the effect of repeated measures of 
maternal serum lipid levels across time on an outcome (aBW) measured 
at one time point using the following model (24):
E(aBW ) =  + (0 + 2 + 4) L0 + (0 + 2) L02 + (2 + 4) L24 +  (1)
In this equation, L0 is the baseline lipid level (6–10 weeks gestation); L02 
is the rate of change of the lipid level during the first half of pregnancy 
(between the first and third time points) defined as L02 = (L2 − L0)/ 
(GA2 − GA0), where GA is the gestational age in fractions of weeks at 
time of measurement; and L24 is the rate of change of the lipid level in the 
second half of pregnancy (between the third and fifth time points). As 
described elsewhere (24), the coefficient for L0 (0 + 2 + 4) defines the 
effect of increasing the lipid level by one unit at any study visit. As such, 
this coefficient describes, for example, the effect of uniformly shifting 
the trajectory upward across all study visits resulting in a cumulative 
effect on aBW. The coefficients for L02 (0 + 2) and L24 (2 + 4) define 
how variation in the rate of weight gain in each visit interval may affect 
variation in aBW.
results
Table 1 presents the sociodemographic and health char-
acteristics of the participants and their newborns. These 
descriptors are stratified on maternal prepregnancy BMI 
categorized as normal weight (≤25.0 kg/m2) and overweight/
obese (>25.0 kg/ m2). While our sample is very homogeneous 
with regard to measures of socioeconomic status and race, 
there was considerable variation in prepregnancy BMI. There 
was a low rate of maternal complications, with only one case 
of confirmed pregnancy-induced hypertension and 13 cases 
of gestational diabetes. There were significant demographic 
differences in women with nonoverweight BMIs compared 
to those with overweight/obese BMIs, including race, age, 
education, and income. Notably, however, controlling for 
these factors did not significantly change our results below 
(analyses not shown). As expected, the infants of overweight/
obese mothers had a significantly higher BW than infants of 
normal weight mothers (Table 1).
Table 2 gives the results of cross-sectional analyses 
describing the relationship of aBW to maternal serum 
lipid levels at five time points spanning pregnancy (6–10, 
10–14, 16–20, 22–26, and 32–36 weeks gestation). These 
analyses are stratified on maternal prepregnancy BMI. We 
find that the relationships of aBW to maternal HDL-C and 
TG differ between these two strata. For obese/overweight 
women, aBW is inversely associated with maternal HDL-C 
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concentrations at all time points starting at 10 weeks ges-
tation. For normal weight women, aBW is not significantly 
associated with maternal HDL-C at any visit. Also shown 
in Table 2, increased maternal serum TG is significantly 
associated with increased aBW for normal weight women at 
10–14 and 22–26 weeks gestation. The effect size is similar 
table 1 characteristics of the study sample
Maternal prepregnancy BMIa
P valueb
All Normal weight Overweight/Obese
N (%)
Sample size 143 72 (50.4) 71 (49.6)
Maternal characteristics
 Raceb
  White 115 (80.4) 61 (84.7) 54 (76.1) 0.0161
  African American 11 (7.7) 2 (2.8) 9 (12.7)
  Asian 7 (4.9) 6 (8.3) 1 (1.4)
  Other 10 (7.0) 3 (4.2) 7 (9.8)
 Ethnicity
  Non-Hispanic 137 (95.8) 71 (98.6) 66 (93.0) 0.1158
  Hispanic 6 (4.2) 1 (1.4) 5 (7.0)
 Maternal ageb
  ≤30 79 (55.2) 33 (45.8) 46 (64.8) 0.0289
  >30 64 (44.8) 39 (54.2) 25 (35.2)
 Parity
  Nulliparous 54 (37.8) 30 (41.7) 24 (33.8) 0.3895
  Multiparous 89 (62.2) 42 (58.3) 47 (66.2)
 Marital status
  Married 118 (82.5) 62 (86.1) 56 (78.9) 0.2786
  Not married 25 (17.5) 10 (13.9) 15 (21.1)
 Highest educational level completedb
  College or less 85 (59.4) 35 (48.6) 50 (70.4) 0.0105
  Postgraduate 58 (40.6) 37 (51.4) 21 (29.6)
 Incomeb
  ≤$80,000 per year 72 (50.3) 29 (40.3) 43 (60.6) 0.0127
  >$80,000 per year 70 (49.0) 43 (59.7) 27 (38.0)
  Missing 1 (0.7) — 1 (1.4)
 Insurance
  Private insurance 125 (87.4) 64 (88.9) 61 (85.9) 0.6234
  Medicaid/Medicare 18 (12.6) 8 (11.1) 10 (14.1)
 Smoking
  Not during pregnancy 132 (92.3) 66 (91.7) 66 (93.0) 1.0000
  During pregnancy 11 (7.7) 6 (8.3) 5 (7.0)
Infant characteristics
 Gender (N, %) 73 (51.0) 38 (52.8) 35 (49.3) 0.7390
  Male 70 (49.0) 34 (47.2) 36 (50.7)
  Female
 Gestational age at birth (days) (mean ± s.d.) 274.0 ± 13.2 273.0 ± 16.1 274.9 ± 9.5 0.4097
 Birth weight (g) (mean ± s.d.)b 3,442.8 ± 543.3 3,324.8 ± 564.0 3,562.6 ± 497.3 0.0084
aBMI categorized as normal weight (≤25.0 kg/m2) and overweight/obese (>25.0 kg/m2) as described in text. bStatistical significance of difference between maternal BMI 
categories using the student t-test for continuous variables and the Fisher exact test for categorical variables.
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in overweight/obese women, but is not statistically signifi-
cant at any visit interval. Several cross-sectional studies have 
reported that maternal mid-pregnancy TG levels are posi-
tively associated with birth weight (12,13,25). The lack of 
a consistently significant TG effect in our sample may be a 
consequence of our modest sample size. Variation in aBW 
is not associated with variation in maternal serum TC or 
LDL-C for either stratum at any time point.
We performed multivariable longitudinal regression analyses 
of the influence of time-dependent variation in maternal serum 
HDL-C on variation in aBW (equation 1) for each BMI stratum. 
For overweight/obese women, the coefficient for L0 in this model 
shows that a 13.0 g decrease in aBW (95% confidence interval: 
−22.6, −3.50) is significantly associated with a 1 mg/ dl increase in 
the magnitude of maternal HDL-C measured at any time point 
during gestation; for normal weight women, a 6.4 g decrease in 
aBW (95% confidence interval: −13.5, 0.69) is associated with a 
1 mg/dl increase in the magnitude of maternal HDL-C. In this 
model, there is no significant relationship between variation 
in aBW and variation in the rate of change in HDL-C in either 
the first (L02) or second (L24) half of pregnancy for either group. 
These results suggest that the magnitude of maternal HDL-C, 
not its trajectory, influences BW across pregnancy.
Finally, in Table 3, we illustrate the magnitude of the effect 
of maternal HDL-C measured between 32 and 36 weeks gesta-
tion on aBW. In this table, we use the regression coefficients 
in Table 2 to calculate the effect of the change in the mean 
maternal HDL-C across quartiles on the change in aBW. For 
overweight/obese women, there is a 347 g decrease in the 
mean aBW between the highest and lowest quartiles of mater-
nal HDL-C. For normal weight women, there is only a 144 g 
decrease in mean aBW between these quartiles. This table 
clearly demonstrates that effects of HDL-C on BW are large 
and different between the strata.
dIscussIon
The regulation and effects of metabolic pathways may be sub-
stantially different in overweight and obese individuals com-
pared to their normal weight counterparts (7–9,26). We have 
shown elsewhere that, overweight/obese women had signifi-
cantly lower TC and LDL-C levels than normal weight women 
in late pregnancy. However, there were no differences in TG or 
HDL-C levels between the strata at any time point (10). Given 
these metabolic differences, this study is among the first to 
evaluate how the relationship between infant BW and mater-
nal serum lipid levels may differ between these two groups.
The most striking finding from our study was a substantially 
larger inverse relationship between BW and HDL-C levels across 
pregnancy in overweight/obese women compared to their nor-
mal weight counterparts. Our results are consistent with smaller 
case–control studies that reported inverse associations between 
table 2 the relationship of gestational age–adjusted birth weight (g) to maternal serum lipid levels (mg/dl) across pregnancy
β (95% CI)
6–10 weeks 10–14 weeks 16–20 weeks 22–26 weeks 32–36 weeks
Normal weight (n = 62) (n = 65) (n = 68) (n = 71) (n = 69)
 TC −0.5 (−3.1, 2.1) −0.6 (−3.1, 1.8) −0.9 (−2.9, 1.2) −1.3 (−2.9, 0.3) −1.2 (−3.1, 0.6)
 LDL-C −0.2 (−3.4, 3.1) −0.9 (−4.0, 2.1) −1.2 (−3.6, 1.3) −1.5 (−3.4, 0.5) −1.3 (−3.4, 0.8)
 HDL-C −4.1 (−10.4, 2.2) −2.1 (−7.7, 3.6) −1.0 (−6.4, 4.4) −4.1 (−8.8, 0.6) −3.6 (−8.6, 1.4)
 TG 1.1 (−0.4, 2.6) 1.5 (0.1, 2.8)* 0.7 (−0.8, 2.1) 1.1 (0.0, 2.1)* 0.9 (−0.1, 1.9)
Obese/Overweight (n = 69) (n = 71) (n = 65) (n = 71) (n = 70)
 TC 0.3 (−3.5, 4.0) 1.5 (−1.8, 4.7) 0.1 (−3.3, 3.5) 0.1 (−2.4, 2.5) 0.4 (−2.3, 3.1)
 LDL-C 2.5 (−1.9, 7.0) 2.8 (−1.1, 6.7) 2.2 (−1.6, 6.1) 0.9 (−2.1, 4.0) 1.0 (−2.0, 4.1)
 HDL-C −7.7 (−16.1, 0.7) −8.0 (−15.6, −0.4)* −9.3 (−16.4, −2.1)* −7.4 (−14.1, −0.7)* −10.0 (−17.5, −2.3)*
 TG 0.4 (−2.3, 3.0) 1.4 (−0.5, 3.2) 0.7 (−1.2, 2.6) 1.5 (0.1, 3.0)* 1.9 (0.6, 3.2)**
CI, confidence interval; HDL-C, high-density lipoprotein; LDL-C, low-density lipoprotein; TC, total cholesterol; TG, triglycerides.
*P ≤ 0.05, **P ≤ 0.01.
table 3 estimate of the effect size of maternal hdl-c 













 1 (lowest) 60.3 ± 3.5 Reference Referencec
 2 70.4 ± 3.0 10.1 −36.4 (−86.9, 14.1)
 3 80.5 ± 2.8 20.2 −72.7 (−173.7, 28.3)
 4 100.3 ± 11.5 40.0 −144 (-344, 56)
Obese/Overweight
 1 (lowest) 60.0 ± 4.1 Reference Referenced
 2 68.8 ± 1.9 8.8 −88 (−154, −20.2)
 3 79.1 ± 4.3 19.1 −191 (−334.3, −43.9)
 4 94.7 ± 8.2 34.7 −347 (−607.3, −79.8)
aBW, birth weight adjusted for gestational age at delivery; CI, confidence interval; 
HDL-C, high-density lipoprotein cholesterol.
aCalculated relative to the mean HDL-C concentration in the lowest quartile for 
each stratum (reference). bCalculated relative to the mean adjusted birth weight 
in the lowest HDL-C quartile for each stratum (reference). cA 1 mg/dl increase in 
HDL is associated with a −3.6 g (95% CI: −8.6, +1.4) change in aBW for normal 
weight women. dA 1 mg/dl increase in HDL is associated with a −10 g (95% CI: 
−17.5, −2.3) change in aBW for obese/overweight women.
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maternal HDL-C levels and risk of macrosomia (5,12,14,15). 
While those studies controlled for maternal prepregnancy 
weight, they did not model the effects of metabolic factors in dif-
ferent BMI groups. Our results suggest that the effect of HDL-C 
on BW is very different in overweight/obese compared to normal 
weight women. In fact, the effect of HDL-C on BW was nearly 
twice as large at every time point in overweight/obese women 
(Table 2). These results suggest that the fetal growth response to 
maternal HDL-C, rather than the HDL-C levels themselves, was 
modified by maternal prepregnancy BMI.
The mechanisms through which maternal HDL-C may influ-
ence BW are poorly understood. However, HDL-C has several 
possible roles that could influence fetal growth and develop-
ment (27). HDL has an important role in cholesterol home-
ostasis required to maintain a favorable sterol balance for the 
extra-embryonic fetal tissues to support fetal growth and devel-
opment (28). For example, the placenta removes HDL from the 
maternal circulation at high rates (29). Perturbation of reverse 
cholesterol transport in overweight and obese women could 
affect the sterol balance in extra-embryonic fetal tissues (30). 
Although it does not cross the placenta, HDL may be able to 
affect fetal metabolism and growth via its effect on the metabolic 
function of extra-embryonic fetal tissues (28). For example, 
when maternal HDL-C concentrations decrease these tissues 
may have compensatory mechanisms for sterol uptake and 
processing that impact fetal growth (28). Maternal overweight 
and obesity may influence these compensatory mechanisms.
In addition to its role in cholesterol transport and home-
ostasis, HDL also has antioxidant, anti-inflammatory, and 
antithrombotic properties (27) that may influence placental 
circulation and fetal growth. For example, reduced levels of 
HDL-C may be associated with placental vasculopathy and 
risk of pre-eclampsia (31). It has been suggested that HDL-C–
related factors associated with oxidative stress, such as paraox-
onase, may influence vascular endothelial function and may be 
involved in the pathophysiology of these perinatal outcomes 
(31,32). The oxidative and inflammatory effects of HDL can 
be modified by a number of cytokines, hormones, and other 
factors (27). Thus, it is possible that dysregulation of adipocy-
tokines in obese women (33) may modulate these effects of 
HDL-C during pregnancy. Ours appears to be the first study 
to suggest that effect of HDL-related pathways on fetal growth 
may be influenced by maternal obesity/overweight status.
A significant strength of our study is the prospective pop-
ulation-based cohort design. Few studies have systematically 
examined the relationship of lipid levels across pregnancy 
on infant outcomes such as BW. However, our study design 
inherently limits study participation to a group of women who 
present for early prenatal care and are able to attend multiple 
study visits. Women without prenatal care or with late, inter-
rupted, or sporadic care are less likely to have been included. 
As a result, maternal sociodemographic covariates show lim-
ited variation. While our sample is homogeneous with regard 
to measures of socioeconomic status and race, there is consid-
erable variation in prepregnancy BMI. Moreover, by focusing 
on this population, many potential confounding factors, both 
measured and unmeasured, are potentially accounted for by 
our sampling allowing us to focus on the effects of maternal 
overweight/obesity.
Our current sample size is modest. As a result, an extensive 
analysis of covariates, including maternal nutrition, illness, and 
behaviors that may influence the observed relationships was 
not possible. However, as noted above, controlling for socio-
demographic variables that differed between the groups did 
not significantly change our results. A larger sample size will 
certainly allow for a more robust examination of physiologic 
biomarkers and epidemiological risk factors that influence the 
relationship of maternal obesity to infant BW. However, even 
with our limited sample size, our analyses consistently demon-
strate that variation in maternal HDL-C levels measured across 
gestation influences infant BW differently in overweight/obese 
women compared to their normal weight counterparts.
Adiposity is associated with a complex set of metabolic and 
endocrinologic changes that may differ among subgroups of 
women with different BMIs (34). The effects of maternal adi-
posity on the growing fetus may be mediated by such changes 
(1,2). However, the physiological mechanisms underlying these 
effects are poorly understood. It has been speculated that meta-
bolic factors in obese women may affect early placental func-
tional development related to lipid and inflammatory responses 
(1). These early changes may alter the effects of both maternal 
lipid metabolism and placental transport of nutrients on the 
growing fetus. Our findings suggest that maternal-fetal HDL-C 
metabolism may have a significant role in these effects. We 
postulate that such differences may be involved in the “physi-
ological programming” of the fetus that influences later risk of 
chronic disease. However, future studies to elucidate the details 
of such mechanisms will be needed. Alterations in maternal 
lipid metabolism may ultimately be a modifiable risk factor to 
prevent the consequences of maternal obesity on the offspring.
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